Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical research

Family History Colorectal Cancer Risk IBD

Analysis based on 9 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026

Sentiment
10
Attention
1
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study may influence future colorectal cancer screening guidelines for IBD patients, potentially affecting diagnostic and monitoring practices. This could impact healthcare providers, diagnostic companies, and pharmaceutical firms developing treatments for IBD and colorectal cancer, though immediate market effects are likely limited.

Healthcare Pharmaceutical Biotechnology

A Swedish registry study from Karolinska Institutet, published in Gastroenterology, found that people with inflammatory bowel disease (IBD) who have two or more first-degree relatives with colorectal cancer face about 2.6 times the risk of developing the disease themselves, compared to IBD patients without such family history. The study included 124,387 people with IBD in Sweden between 1996 and 2023, followed for a median of eleven years, during which 1,882 developed colorectal cancer. In contrast, IBD patients with a first-degree relative diagnosed before age 50 had only a just under 50% higher risk. The findings suggest that the number of affected relatives may be a more important risk marker than the age of diagnosis, potentially influencing future screening guidelines. The study used Swedish national registers including the Patient Register, Cancer Register, Cause of Death Register, Multigenerational Register, and the ESPRESSO cohort. Funding came from Sweden — Swedish Research Council, American Cancer Society, Sweden — Vinnova, Sweden — Stockholm County, Karolinska Institutet, and ERA PerMed. The research is observational and does not prove causation, but highlights the importance of detailed family history in risk assessment for IBD patients.

per
Lead author and senior consultant, key figure in the research, enhancing her professional standing.
Importance 80.0 Sentiment 10.0
per
Co-author and senior consultant, key figure in the research, contributing to the findings.
Importance 80.0 Sentiment 10.0
cnt
Country where the study was conducted, benefiting from advanced healthcare research and registry data.
Importance 40.0 Sentiment 10.0
oth
Affiliated hospital of lead author Asa Everhov, contributing to the study's clinical relevance.
Importance 30.0 Sentiment 5.0
oth
Affiliated hospital of co-author Ola Olen, involved in the research.
Importance 30.0 Sentiment 5.0
govactor
Funding agency supporting the research, reinforcing its commitment to medical science.
Importance 20.0 Sentiment 5.0
ngo
Funding agency supporting cancer research, aligning with its mission.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
per
Co-author contributing to the study.
Importance 20.0 Sentiment 5.0
+ 3 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.